Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Income from Continuing Operations (2018 - 2025)

BioNexus Gene Lab's Income from Continuing Operations history spans 8 years, with the latest figure at 708991.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 52.63% year-over-year to 708991.0; the TTM value through Sep 2025 reached 2289821.0, down 126.79%, while the annual FY2024 figure was 1591354.0, 38.46% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 708991.0 at BioNexus Gene Lab, down from 616172.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 351515.0 in Q4 2023 and bottomed at 2609189.0 in Q3 2023.
  • The 5-year median for Income from Continuing Operations is 63621.0 (2024), against an average of 300528.53.
  • The largest YoY upside for Income from Continuing Operations was 771.48% in 2023 against a maximum downside of 3271.0% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 115979.0 in 2021, then crashed by 145.14% to 52349.0 in 2022, then soared by 771.48% to 351515.0 in 2023, then plummeted by 197.1% to 341331.0 in 2024, then tumbled by 107.71% to 708991.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Income from Continuing Operations are 708991.0 (Q3 2025), 616172.0 (Q2 2025), and 623327.0 (Q1 2025).